Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
Study sponsor: Kiniksa Pharmaceuticals (UK), Ltd.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-05-29Actual
Enrollment · participants86Actual
Source updated2023-09-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.